Tim Sauer
Overview
Explore the profile of Tim Sauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1099
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stasik S, Eckardt J, Rollig C, Baldus C, Platzbecker U, Serve H, et al.
Br J Haematol
. 2025 Mar;
PMID: 40041934
IKZF1 mutations are recurrent alterations in acute myeloid leukaemia (AML), and hotspot point mutation, N159S, has recently been associated with unique gene expression and adverse risk. To better understand the...
2.
Ruhnke L, Bill M, Zukunft S, Eckardt J, Schafer S, Stasik S, et al.
Blood Adv
. 2024 Nov;
PMID: 39504561
In 2022, the European LeukemiaNet (ELN) risk stratification for patients with AML has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) evaluating 1,570...
3.
Unglaub J, Unglaub J, Schlenk R, Middeke J, Middeke J, Krause S, et al.
Blood Adv
. 2024 Sep;
9(2):375-385.
PMID: 39293081
The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing...
4.
Sedloev D, Chen Q, Unglaub J, Schanda N, Hao Y, Besiridou E, et al.
J Hematol Oncol
. 2024 Sep;
17(1):85.
PMID: 39285441
Background: Relapsed and refractory acute myeloid leukemia (AML) carries a dismal prognosis. CAR T cells have shown limited efficacy in AML, partially due to dysfunctional autologous T cells and the...
5.
Rollig C, Steffen B, Schliemann C, Mikesch J, Alakel N, Herbst R, et al.
J Clin Oncol
. 2024 Sep;
43(1):65-74.
PMID: 39284116
Purpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60...
6.
Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, et al.
Haematologica
. 2024 Apr;
109(8):2469-2477.
PMID: 38654660
In newly diagnosed acute myeloid leukemia (AML), immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pretherapeutic risk factors....
7.
Sharma S, Mehta N, Sauer T, Rollins L, Dittmer D, Rooney C
Blood Adv
. 2024 Apr;
8(13):3360-3371.
PMID: 38640255
The remarkable efficacy of Epstein-Barr virus (EBV)-specific T cells for the treatment of posttransplant lymphomas has not been reproduced for EBV-positive (EBV+) malignancies outside the transplant setting. This is because...
8.
Han H, Wang L, Ding Y, Neuber B, Huckelhoven-Krauss A, Lin M, et al.
Blood Adv
. 2024 Feb;
8(11):2675-2690.
PMID: 38359409
Graft-versus-host disease (GVHD) occurs in about 10% to 33% of patients receiving "allogeneic" or "autologous" chimeric antigen receptor T (CAR-T) cells after preceding allogeneic hematopoietic stem cell transplantation (allo-HSCT) due...
9.
Farid K, Sauer T, Schmitt M, Muller-Tidow C, Schmitt A
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201486
Purpose: We aimed to identify subsets of patients who benefit from emergency LA and to establish a therapeutic algorithm for AML patients with hyperleukocytosis. Methods: In this single-center retrospective cohort...
10.
Mathioudaki A, Wang X, Sedloev D, Huth R, Kamal A, Hundemer M, et al.
Blood
. 2024 Jan;
143(13):1269-1281.
PMID: 38197505
Acute myeloid leukemia (AML) is a hematologic malignancy for which allogeneic hematopoietic cell transplantation (allo-HCT) often remains the only curative therapeutic approach. However, incapability of T cells to recognize and...